This study demonstrates that Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the incidence of liver-related events, including hepatocellular carcinoma (HCC), in 28,426 patients with concurrent diabetes and chronic hepatitis B/C using data from the Korean nationwide cohort. Here, SLC5A2 is linked to diabetes mellitus.